{"id":"NCT00227305","sponsor":"AstraZeneca","briefTitle":"Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder","officialTitle":"A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUELâ„¢) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2005-09-28","resultsPosted":"2012-10-05","lastUpdate":"2013-01-08"},"enrollment":381,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"quetiapine fumarate","otherNames":["Seroquel"]}],"arms":[],"summary":"The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.","primaryOutcome":{"measure":"Incidence and Nature of Adverse Events (AEs)","timeFrame":"from open label to week 26+ 30 days","effectByArm":[{"arm":"Quetiapine","deltaMin":321,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":48,"countries":["United States","India","Malaysia","Philippines","Poland","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":["24024534"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":380},"commonTop":["SOMNOLENCE","INCREASED APPETITE","SEDATION","WEIGHT INCREASED","HEADACHE"]}}